Rani Therapeutics announced that it has entered into a collaboration with MedImmune, to evaluate Rani's novel oral drug delivery platform. The companies have agreed to conduct feasibility studies over the next two years, in which Rani will test select biologic molecules in the area of metabolic disease to evaluate the oral delivery of these molecules. Upon successful completion of the feasibility studies, AstraZeneca and MedImmune will have the right to enter into a more extensive collaboration with Rani.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.7 USD | +3.06% |
|
-1.07% | +11.45% |
Jun. 24 | Rani Therapeutics Partners With ProGen for Oral Obesity Treatment Development; Shares Rise | MT |
Jun. 24 | Transcript : Rani Therapeutics Holdings, Inc. - Special Call |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.45% | 97.32M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- RANI Stock
- News Rani Therapeutics Holdings, Inc.
- Rani Therapeutics Announces Collaboration with Medimmune in the Metabolic Disease Field